Three simple, precise and accurate spectrophotometric methods have been developed for the estimation of emtricitabine in bulk and pharmaceutical formulations. Emtricitabine exhibits maximum absorbance at 282.0 nm in method A. The amplitude shows at 269.0-298.0 nm in method B and method C is based on calculation of area under curve (AUC) in the wavelength region of 272.0-292.0 nm. The drug obeys the Beer-Lambert's law in the concentration range of 1.0-100 µg/mL in all three methods. The methods were validated by following the analytical performance parameters suggested by the International Conference on Harmonization. All validation parameters were within the acceptable range. The developed methods were successfully applied to estimate the amount of emtricitabine in bulk and pharmaceutical dosage forms.
Introduction
Emtricitabine is an analogue of cytidine. The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA. The different analytical methods that are reported for its determination includes HPLC [2] [3] [4] [5] [6] [7] , LC/MS 8, 9 and spectroscopy 10, 11 . The aim of the present work is to develop new validated spectrophotometric methods for the estimation of emtricitabine in bulk and pharmaceutical dosage forms. 
Experimental
Emtricitabine gift sample was supplied by Piramal HC (India) and commercial capsule formulations from the local market were purchased from local market. Methanol (Merck), Octane-1 sulfonic acid sodium salt (Spectrochem) and ortho phosphoric acid (AR) (Merck) were used in the present study.
Instrumentation
A double beam UV-Vis spectrophotometer (UV-1800, Shimadzu, Japan) connected to computer loaded with spectra manager software UV Probe was employed with spectral band-width of 1 nm wavelength accuracy of ±0.3 nm with a pair of 10 mm matched quartz cells. All weights were taken on electronic balance (Denver, Germany).
Preparation of stock solution
The stock solution of emtricitabine was prepared by dissolving accurately 25 mg of drug in methanol in a 25 mL volumetric flask to obtain a concentration of 1000 µg/mL. From this solution, 2.5 mL was taken and diluted with 0.02 M Octane 1-sulfonic acid buffer (pH 3.5 adjusted with o-phosphoric acid) in a 25 mL volumetric flask to prepare a working standard solution (100 µg/mL).
Method A (Zero order spectrometry)
Series dilutions of standard solutions were prepared in 10 mL volumetric flasks with buffer (pH 3.5) to get the concentration ranging from 0.1-100 µg/mL. The above solutions were scanned over the range of 400 nm to 200 nm against reagent blank. The λ max was found to be 282.0 nm and the results were in good agreement with Beer-Lambert's law. The calibration curve was constructed by plotting concentration against absorbance at 282.0 nm ( Figure 2 ). 
Method B (First-derivative spectrometry)
The above mentioned zero order spectrum were derivatised to get first-order derivative spectra ( Figure 3 ). This spectrum shows minima (298 nm) as well as maxima (269 nm) and therefore the amplitude was chosen for the analytical determinations. 
Method C (Area under curve)
The AUC (area under curve) method involves the value with respect to the selected wavelength region (272-292 nm). The calibration curve was constructed by potting concentration against AUC.
Estimation of emtricitabine in tablets
Twenty tablets were weighed, finely powdered and equivalent to 25 mg of the drug was weighed from each brand and extracted with methanol, sonicated and make up to volume with methanol in three separate 25 mL volumetric flasks (1 mg/mL) and filtered. The dilutions were made from this stock with buffer (pH 3.5), as per the requirement. Different sample solutions were prepared and analyzed against blank.
Method validation

Precision
The Inter-day precision was determined on three different days at three different levels (10, 20 and 50 µg/mL) and the intraday precision was determined at three different levels (10, 20 and 50 µg/mL) by the same analyst. The %RSD values were found to be in the range 0.42-0.73 (Intraday) and 0.56-0.92 (Interday) which are less than 2% indicating that the mehtod is more precise.
Accuracy
Recovery studies were carried out by adding different amounts (80%, 100% and 120%) of bulk samples of emtricitabine within the linearity range to pre analyzed formulation as per ICH guidelines and the %RSD values were found to be less than 2% (0.56-1.28%) indicating that the method is more accurate.
Results and Discussion
The calibration curve was obtained for a series of concentration in the range of 0.1 -100 µg/mL for all the three methods. It was found to be linear and hence, suitable for the estimation of the drug. The optical characteristics were summarized in Table 1 . Regression analysis of Beer's law plot revealed a good correlation. The effects of various excipients generally present in the tablet dosage forms of EMT were investigated. 12 . The precision was measured in terms of repeatability, which was determined at three levels (10, 20 and 50 µg/mL)\ and the %RSD were found to be less than 2.0% (0.42-0.73 (Intraday) and 0.56-0.92 (Interday)) showing that the method is more precise. The accuracy study was conducted by adding known quantities of the standard EMT solution (80%, 100% and 120%) to a particular concentration of preanalyzed formulations and the mixtures were analyzed and the % recovery values were found to be within the range of 98.27-100.83% (%RSD = 0.56-1.28%). This showed that the recovery of EMT by the proposed method is satisfactory. Thus it can be concluded that the methods developed in the present investigation are simple, sensitive, accurate, rapid and precise. Hence, the proposed methods can be successfully applied for the estimation of emtricitabine in tablet dosage forms. 
Conclusion
Emtricitabine obeys Beer-Lambert's law in the concentration range of 0.1-100 µg/mL in all the four methods and the %RSD in precision and accuracy studies was found to be less than 2.0% indicating that the methods are more precise and accurate and therefore, can be employed for the estimation of emtricitabine in pharmaceutical formulations.
